儿童血浆米托坦浓度测定与治疗药物监测

    Determination of Plasma Mitotane Concentration and Therapeutic Drug Monitoring in Children

    • 摘要:
      目的  建立HPLC法测定血浆中米托坦浓度并用于儿童治疗药物监测。
      方法 采用Agilent ZORBAX Eclipse XDB-C18(4.6 mm×150 mm,5 μm)色谱柱,以水-乙腈(15∶85)为流动相等度洗脱;流速1.0 mL·min−1,柱温35 ℃,检测波长为230 nm。
      结果 米托坦浓度在1.0 ~50.0 μg·mL−1内线性关系良好,准确度、精密度、提取回收率与稳定性均符合相关指导原则要求。成功应用于7例肾上腺皮质患儿共25份血浆样本测定,实测谷浓度为1.19~27.30 μg·mL−1,仅8份(32%)浓度位于指南推荐治疗窗内,14份(56%)的样本浓度低于推荐治疗窗(<14 μg·mL−1),另有3份(12%)样本浓度高于治疗窗。本组7例患儿中,4例经剂量调整及不良反应干预后达治疗窗,3例因不耐受胃肠道反应与神经毒性等无法上调剂量,未达治疗窗浓度。
      结论 本研究优化的HPLC操作简便、稳定性好,可满足儿童米托坦剂量调整期血药浓度的准确定量检测需求。儿童患者米托坦血药浓度个体差异大、不良反应常见,且现有治疗窗指导其给药调整存在一定局限性,应长期开展治疗药物监测,优化专门针对儿童患者的治疗窗。

       

      Abstract:
      OBJECTIVE To establish an HPLC method for the determination of mitotane in plasma and apply it to therapeutic drug monitoring in children.
      METHODS An Agilent ZORBAX Eclipse XDB-C18(4.6 mm×150 mm, 5 μm) column was used. The mobile phase consisted of water and acetonitrile(15∶85) with isocratic elution. The flow rate was 1.0 mL·min−1, the column temperature was 35 ℃, and the detection wavelength was 230 nm.
      RESULTS Mitotane showed good linearity within 1.0–50.0 μg·mL−1. The accuracy, precision, extraction recovery, and stability all met the guidance requirements. A total of 25 plasma samples from 7 adrenocortical carcinoma children were analyzed, with trough concentrations ranging from 1.19 to 27.30 μg·mL−1, only 8 samples(32%) had concentrations within the guideline-recommended therapeutic window, 14(56%) were below the recommended window(<14 μg·mL−1), and the remaining 3(12%) were above it. Among the 7 pediatric patients, 4 reached the therapeutic window after dose adjustment and management of adverse reactions, whereas 3 did not, as adverse reactions precluded further dose escalation.
      CONCLUSION The HPLC method optimized in this study is simple to operate and stable, effectively meeting the detection requirements for accurate quantification of pediatric plasma mitotane concentrations during the dose-adjustment period. Pediatric patients show marked interindividual variability in mitotane concentrations and frequently develop adverse reactions, and the existing therapeutic window has limitations in guiding dose adjustment; therefore, long-term therapeutic drug monitoring should be implemented to optimize a pediatric-specific therapeutic window.

       

    /

    返回文章
    返回